1-20 of 97
poly(adp-ribose) polymerase inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

Joshua F Ransom, PhD, Aaron Galaznik, MDMBA, Emelly Rusli, Bruno Lempernesse, MS, Marc Berger, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4895.
https://doi.org/10.1182/blood-2019-129086
Published: 2019
Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3779.
https://doi.org/10.1182/blood-2019-131364
Published: 2019
Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3909.
https://doi.org/10.1182/blood-2019-129168
Published: 2019
Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3756.
https://doi.org/10.1182/blood-2019-125355
Published: 2019
Journal Articles

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Maria R. Baer, MD, Stephen Baylin, MD, Michael Topper, BS, Feyruz V. Rassool, BSc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3763.
https://doi.org/10.1182/blood-2019-129535
Published: 2019
Journal Articles

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin, PhD, Jie Jin, PhD, Jiajia Pan, Yungui Wang, PhD, Shujuan Huang, Shihui Mao, Qing Ling, Jinghan Wang, MD PhD, Chenying Li
Journal: Blood
Blood (2019) 134 (Supplement_1): 5041.
https://doi.org/10.1182/blood-2019-125221
Published: 2019
Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4222.
https://doi.org/10.1182/blood-2019-130814
Published: 2019
Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5755.
https://doi.org/10.1182/blood-2019-123571
Published: 2019
Journal Articles

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Harmony Estelle Black, BSc, Satpal Jhujh, Grant S Stewart, BSc, PhD, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1255.
https://doi.org/10.1182/blood-2019-129828
Published: 2019
Journal Articles

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Ashwin Kishtagari, MBBS, Yihong Guan, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Jibran Durrani, Edward F Greenberg, MD, Xiaorong Gu, PhD, Feng Pan, PhD, Valeria Visconte, PhD, Dewen You, PhD, Guangbo Qu, PhD, Amy C Graham, BS, MS, Bartlomiej P. Przychodzen, Thomas Laframboise, PhD, Hideki Makishima, MD PhD, Daniel Gackowski, PhD, Ryszard Ólinski, Professor, Yu-Wei Cheng, PhD, Mikkael A. Sekeres, MD MS, Mingjiang Xu, MD PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1200.
https://doi.org/10.1182/blood-2019-132005
Published: 2019
Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Geethu Emily Thomas, PhDMSc,BSc, Grace Egan, MD, Laura Garcia Prat, Boaz Nachmias, MD PhD, Jordan M Chin, Fieke W Hoff, BSc, Kerstin Kaufmann, PhD, Rose Hurren, BSc, Marcela Gronda, MSc, Neil MacLean, Xiaoming Wang, Veronique Voisin, PhD, Aaron Botham, Andrea Arruda, Mark D. Minden, MD PhD, Gary D Bader, Steven M. Kornblau, MD, John E. Dick, PhD, Aaron D Schimmer, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2532.
https://doi.org/10.1182/blood-2019-123121
Published: 2019
Journal Articles

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Haruka Hiroki, MD, Masatoshi Takagi, MD PhD, Yuko Ishi, MD, Jinhua Piao, Tomohiro Morio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3367.
https://doi.org/10.1182/blood-2019-127853
Published: 2019
Journal Articles

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Anna L Brown, PhD, Milena Babic, BMPharBio (Hons), Andreas Schreiber, Jinghua Feng, PhD, Julia Dobbins, BSc (Hons), Peer Arts, PhD, Paul Wang, PhD, Kerry Phillips, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Parvathy Venugopal, PhD MSc, BSc, Susan Branford, PhD FFSc (RCPA), Nicola Poplawski, MD, Christopher N Hahn, PhD, Hamish S Scott, PhD FFSc (RCPA)
Journal: Blood
Blood (2019) 134 (Supplement_1): 3794.
https://doi.org/10.1182/blood-2019-131642
Published: 2019
Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

David C. Koomen, BS, Mark B. Meads, PhD, Dario M. Magaletti, Joy D. Guingab, PhD, Paula S. Oliveira, Bin Fang, PhD, Victoria Izumi, MS, Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria Silva, Raghunandanreddy Alugubelli, MS, Gabe De Avilla, Alex Tungeskiv, Eric A. Welsh, PhD, Laurel E. Meke, Wei Zhang, PhD, Steven A. Eschrich, PhD, Timothy J. Garrett, PhD, Ariosto Siqueira Silva, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5534.
https://doi.org/10.1182/blood-2019-132001
Published: 2019
Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1371.
https://doi.org/10.1182/blood-2019-130427
Published: 2019
Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3107.
https://doi.org/10.1182/blood-2019-128245
Published: 2019
Journal Articles

PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions

Margaret Nieborowska-Skorska, Paulina Podszywalow-Bartnicka, Silvia Maifrede, Bac Viet Le, Monika Toma, Peter Valent, Tomasz Sliwinski, Wayne Childers, Katarzyna Piwocka, Alexei Tulin, Tomasz Skorski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3000.
https://doi.org/10.1182/blood-2018-99-115041
Published: 2018
Journal Articles

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Tyler Maclay, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3963.
https://doi.org/10.1182/blood-2018-99-119373
Published: 2018
Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3886.
https://doi.org/10.1182/blood-2018-99-117294
Published: 2018
Journal Articles

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Priya Sriskandarajah, MBBS, BSc, MRCP, Kevin Boyd, Wen Xu, MD, Irene Moreno Candilejo, MD, Sidra Ellis, Amy Price, Amy L Sherborne, PhD, James Croft, MBBS, BSc, Vallari Shah, MBBS, Joanna Dawes, PhD, Mona Parmar, Alison Turner, Emma Hall, BSc, MSc, PhD, Nina Tunariu, MBBS, MDes, MRCP, FRCR, Juanita S Lopez, MB BChir, MRCP, PhD, Johann S. de Bono, Udai Banerji, MBBS, MD DNB, PhD FRCP, Martin Kaiser, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3237.
https://doi.org/10.1182/blood-2018-99-111821
Published: 2018